Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial‐unfit patients and subsequent therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial‐unfit patients and subsequent therapy

Published:2020-12-27 Issue:1 Volume:193 Page:101-112
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br. J. Haematol.

Author:

Park Sung‐Soo¹²^ORCID,Min Byun Ja³^ORCID,Yoon Sung‐Soo³^ORCID,Kim Kihyun⁴,Jung Sung‐Hoon⁵^ORCID,Lee Je‐Jung⁵,Min Chang‐Ki¹²

Affiliation:

1. Department of Hematology Seoul St. Mary’s Hematology HospitalCollege of MedicineThe Catholic University of Korea SeoulKorea

2. Leukemia Research InstituteThe Catholic University of Korea SeoulKorea

3. Hematology and Medical Oncology Department of Internal Medicine Seoul National University Hospital SeoulKorea

4. Division of Hematology‐Oncology Department of Medicine Samsung Medical CenterSungkyunkwan University School of Medicine SeoulKorea

5. Department of Hematology‐Oncology Chonnam National University Hwasun Hospital and Chonnam National University Hwasun Korea

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17071

Reference30 articles.

1. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

2. Ten Years of Improvement in the Management of Multiple Myeloma: 2000-2010

3. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)

4. Improved survival in multiple myeloma and the impact of novel therapies

5. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Daratumumab in Indian patients with relapsed and refractory multiple myeloma: a prospective, multicenter, phase IV study;Future Oncology;2023-12-20

2. Access to Chronic Pain Services for Adults from Minority Ethnic Groups in the United Kingdom (UK): a Scoping Review;Journal of Racial and Ethnic Health Disparities;2023-10-16

3. Role of daratumumab in the frontline management of multiple myeloma: a narrative review;Expert Review of Hematology;2023-08-18

4. Comparisons of efficacy between frontline treatment with bortezomib-melphalan-prednisone and lenalidomide-dexamethasone for transplant-ineligible multiple myeloma: a multicenter real-world based registry report, CAREMM-2102 study;Journal of Cancer Research and Clinical Oncology;2023-07-07

5. Tumor Lysis Syndrome Associated with Monoclonal Antibodies in Patients with Multiple Myeloma: A Pharmacovigilance Study Based on the FAERS Database;Clinical Pharmacology & Therapeutics;2023-05-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3